Blood Res.  2022 Jun;57(2):101-105. 10.5045/br.2022.2021204.

Diabetes mellitus and diabetic nephropathy: a review of the literature on hemostatic changes in coagulation and thrombosis

• Alsharidah AS

• KMID: 2530873
• DOI: http://doi.org/10.5045/br.2022.2021204

Abstract

Vascular complications lead to morbidity and mortality in patients with diabetes. Diabetic nephropathy (DN) is one of the main life-threatening problems for these patients, as it is the main cause of end-stage renal disease. This study aimed to measure the clinical effects of diabetes in patients with diabetes and in patients with diabetic nephropathy. Improved hypoglycemic control in patients with diabetes could impressively reduce platelet hyperreactivity, and oxidative stress alters the levels of many coagulation and thrombosis factors, resulting in an abnormal hemostasis and impaired levels of numerous serum markers. Most studies have revealed that coagulation factor levels are high in patients with diabetes and nephrodiabetes. Serum inflammatory factors, and coagulation and endothelial functions are good predictors of diabetic nephropathy. This literature review was conducted with access to scholarly databases and Google Scholar through Qassim University, and it analyzes studies from early 2010 until November 2020. Many studies have inferred that diabetes severely affects hemostasis and increases the risk of cardiovascular disease.

Keyword

Diabetes; Coagulation; Thrombosis; Nephropathy

Reference

1. International Diabetes Federation. 2013. IDF Atlas. 6th ed. International Diabetes Federation;Brussels, Belgium: at http://www.idf.org/diabetesatlas. Accessed October 2, 2021.

2. American Diabetes Association. 2015; (2) Classification and diagnosis of diabetes. Diabetes Care. 38(Suppl):S8–16. DOI: 10.2337/dc15-S005. PMID: 25537714.

3. Cho NH, Shaw JE, Karuranga S, et al. 2018; IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 138:271–81. DOI: 10.1016/j.diabres.2018.02.023. PMID: 29496507.

4. Gray SP, Jandeleit-Dahm K. 2014; The pathobiology of diabetic vascular complications--cardiovascular and kidney disease. J Mol Med (Berl). 92:441–52. DOI: 10.1007/s00109-014-1146-1. PMID: 24687627.

5. Ilyas S, Waheed U, Saboor M. 2013; Coagulation abnormalities in diabetes mellitus. J Public Health Biol Sci. 2:308–12.

6. Reutens AT. 2013; Epidemiology of diabetic kidney disease. Med Clin North Am. 97:1–18. DOI: 10.1016/j.mcna.2012.10.001. PMID: 23290726.

7. American Diabetes Association. 2014; Diagnosis and classification of diabetes mellitus. Diabetes Care. 37(Suppl 1):S81–90. DOI: 10.2337/dc14-S081. PMID: 24357215.

8. Umanath K, Lewis JB. 2018; Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 71:884–95. DOI: 10.1053/j.ajkd.2017.10.026. PMID: 29398179.

9. Sobczak AIS, Stewart AJ. 2019; Coagulatory defects in type-1 and type-2 diabetes. Int J Mol Sci. 20:6345. DOI: 10.3390/ijms20246345. PMID: 31888259. PMCID: PMC6940903.

10. Stratmann B, Tschoepe D. 2009; Atherogenesis and atherothrombosis-- focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab. 23:291–303. DOI: 10.1016/j.beem.2008.12.004. PMID: 19520304.

11. Grant PJ. 2005; Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin. 21(Suppl 1):S5–12. DOI: 10.1185/030079905X36431. PMID: 15811194.

12. Pan L, Ye Y, Wo M, et al. 2018; Clinical significance of hemostatic parameters in the prediction for type 2 diabetes mellitus and diabetic nephropathy. Dis Markers. 2018:5214376. DOI: 10.1155/2018/5214376. PMID: 29511389. PMCID: PMC5817264.

13. Lewis P, Stefanovic N, Pete J, et al. 2007; Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation. 115:2178–87. DOI: 10.1161/CIRCULATIONAHA.106.664250. PMID: 17420349.

14. Leopold JA, Loscalzo J. 2009; Oxidative risk for atherothrombotic cardiovascular disease. Free Radic Biol Med. 47:1673–706. DOI: 10.1016/j.freeradbiomed.2009.09.009. PMID: 19751821. PMCID: PMC2797369.

15. Lancellotti S, De Filippis V, Pozzi N, et al. 2010; Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: a new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med. 48:446–56. DOI: 10.1016/j.freeradbiomed.2009.11.020. PMID: 19969076.

16. De Filippis V, Lancellotti S, Maset F, et al. 2012; Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J. 442:423–32. DOI: 10.1042/BJ20111798. PMID: 22091998.

17. Chen J, Fu X, Wang Y, et al. 2010; Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood. 115:706–12. DOI: 10.1182/blood-2009-03-213967. PMID: 19812385. PMCID: PMC2810979.

18. Sun J, Liu C. 2018; Correlation of vascular endothelial function and coagulation factors with renal function and inflammatory factors in patients with diabetic nephropathy. Exp Ther Med. 16:4167–71. DOI: 10.3892/etm.2018.6718. PMID: 30402157. PMCID: PMC6200961.

19. Randriamboavonjy V, Fleming I. 2012; Platelet function and signaling in diabetes mellitus. Curr Vasc Pharmacol. 10:532–8. DOI: 10.2174/157016112801784639. PMID: 22338567.

20. Ferroni P, Basili S, Falco A, Davì G. 2004; Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2:1282–91. DOI: 10.1111/j.1538-7836.2004.00836.x. PMID: 15304032.

21. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. 2001; Platelet dysfunction in type 2 diabetes. Diabetes Care. 24:1476–85. DOI: 10.2337/diacare.24.8.1476. PMID: 11473089.

22. Sato C, Shikata K, Hirota D, et al. 2011; P-selectin glycoprotein ligand-1 deficiency is protective against obesity-related insulin resistance. Diabetes. 60:189–99. DOI: 10.2337/db09-1894. PMID: 20971965. PMCID: PMC3012171.

23. Lord ST. 2011; Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol. 31:494–9. DOI: 10.1161/ATVBAHA.110.213389. PMID: 21325671. PMCID: PMC3070401.

24. Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L. 2012; Factor XIII, clot structure, thrombosis. Thromb Res. 129:382–7. DOI: 10.1016/j.thromres.2011.11.040. PMID: 22197181.

25. Dhas Y, Banerjee J, Mishra N. 2020; Blood viscosity, glycemic markers and blood pressure: a study in middle-aged normotensive and hypertensive type 2 diabetics. Indian J Clin Biochem. 35:102–8. DOI: 10.1007/s12291-018-0798-y. PMID: 32071502. PMCID: PMC6995473.

26. Kafle DR, Shrestha P. 2010; Study of fibrinogen in patients with diabetes mellitus. Nepal Med Coll J. 12:34–7. PMID: 20677607.

27. Dunn EJ, Ariëns RA, de Lange M, et al. 2004; Genetics of fibrin clot structure: a twin study. Blood. 103:1735–40. DOI: 10.1182/blood-2003-07-2247. PMID: 14604965.

28. Ajjan R, Grant PJ. 2006; Coagulation and atherothrombotic disease. Atherosclerosis. 186:240–59. DOI: 10.1016/j.atherosclerosis.2005.10.042. PMID: 16343508.

29. Schneppenheim R. 2011; The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res. 128(Suppl 1):S3–7. DOI: 10.1016/S0049-3848(12)70002-6. PMID: 22221847.

30. Ruggeri ZM. 2007; The role of von Willebrand factor in thrombus formation. Thromb Res. 120(Suppl 1):S5–9. DOI: 10.1016/j.thromres.2007.03.011. PMID: 17493665. PMCID: PMC2702526.

31. Jenkins PV, O'Donnell JS. 2006; ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion. 46:1836–44. DOI: 10.1111/j.1537-2995.2006.00975.x. PMID: 17002642.

32. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. 2006; Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 4:1396–404. DOI: 10.1111/j.1538-7836.2006.01959.x. PMID: 16706987.

33. Soejima K, Mimura N, Hirashima M, et al. 2001; A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 130:475–80. DOI: 10.1093/oxfordjournals.jbchem.a003009. PMID: 11574066.

34. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. 2008; ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 205:2065–74. DOI: 10.1084/jem.20080130. PMID: 18695007. PMCID: PMC2526201.

35. Monti M. 2020; Von Willebrand factor, ADAMTS13 and neutrophil extracellular traps: allies in cancer-associated thrombosis and tumor progression? Hematol Med Oncol. 5:1000207. DOI: 10.15761/HMO.1000207.

36. Gragnano F, Sperlongano S, Golia E, et al. 2017; The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm. 2017:5620314. DOI: 10.1155/2017/5620314. PMID: 28634421. PMCID: PMC5467347.

37. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. 2007; ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 138:534–40. DOI: 10.1111/j.1365-2141.2007.06688.x. PMID: 17608762.

38. Zhao Y, Zhang J, Zhang J, Wu J. 2011; Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 6:e16470. DOI: 10.1371/journal.pone.0016470. PMID: 21297995. PMCID: PMC3030587. PMID: ea971a6fbedf41f9beba8a0d932ea4d9.

39. Bembde AS. 2012; A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control. Indian J Hematol Blood Transfus. 28:105–8. DOI: 10.1007/s12288-011-0116-9. PMID: 23730017. PMCID: PMC3332265.

40. Sapkota B, Shrestha SK, Poudel S. 2013; Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus. BMC Res Notes. 6:485. DOI: 10.1186/1756-0500-6-485. PMID: 24274772. PMCID: PMC4222085.

41. Mohan G, Kaur R, Aggarwal A, Singh P. 2017; To study levels of serum fibrinogen in type 2 diabetes mellitus and its association with diabetic microvascular complications. Int J Adv Med. 4:10–4. DOI: 10.18203/2349-3933.ijam20170072.

42. Kaur S, Singh P, Indu V, Singla G. 2012; Fibrinogen, Lp(a), microalbuminuria and left ventricular mass index: cardiovascular disease risk factors in diabetes. Indian J Clin Biochem. 27:94–6. DOI: 10.1007/s12291-011-0184-5. PMID: 23277719. PMCID: PMC3286583.

43. Lominadze D, Dean WL, Tyagi SC, Roberts AM. 2010; Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf). 198:1–13. DOI: 10.1111/j.1748-1716.2009.02037.x. PMID: 19723026. PMCID: PMC2803614.

44. Madan R, Gupt B, Saluja S, Kansra UC, Tripathi BK, Guliani BP. 2010; Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India. 58:481–4. PMID: 21189694.

45. Kubisz P, Chudý P, Stasko J, et al. 2010; Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus. Acta Diabetol. 47:119–24. DOI: 10.1007/s00592-009-0127-2. PMID: 19436948.

46. Dayer MR, Mard-Soltani M, Dayer MS, Alavi SM. 2011; Interpretation of correlations between coagulation factors FV, FVIII and vWF in normal and type 2 diabetes mellitus patients. Pak J Biol Sci. 14:552–7. DOI: 10.3923/pjbs.2011.552.557. PMID: 22032085.

47. Saboor M, Moinuddin , Ajmal M, Ilyas S. 2014; Functional status of vascular endothelium in diabetes mellitus. J Ayub Med Coll Abbottabad. 26:239–43. PMID: 25603686.

48. Oggianu L, Lancellotti S, Pitocco D, et al. 2013; The oxidative modification of von Willebrand factor is associated with thrombotic angiopathies in diabetes mellitus. PLoS One. 8:e55396. DOI: 10.1371/journal.pone.0055396. PMID: 23383177. PMCID: PMC3561310.

49. Domingueti CP, Dusse LM, Fóscolo RB, et al. 2015; Von Willebrand factor, ADAMTS13 and D-dimer are correlated with different levels of nephropathy in type 1 diabetes mellitus. PLoS One. 10:e0132784. DOI: 10.1371/journal.pone.0132784. PMID: 26168189. PMCID: PMC4500451.

50. Shao Y, Lv C, Yuan Q, Wang Q. 2016; Levels of serum 25(OH)VD3, HIF-1α, VEGF, vWf, and IGF-1 and their correlation in type 2 diabetes patients with different urine albumin creatinine ratio. J Diabetes Res. 2016:1925424. DOI: 10.1155/2016/1925424. PMID: 27069929. PMCID: PMC4812448.

51. Taniguchi S, Hashiguchi T, Ono T, et al. 2010; Association between reduced ADAMTS13 and diabetic nephropathy. Thromb Res. 125:e310–6. DOI: 10.1016/j.thromres.2010.02.013. PMID: 20307901.